A Study of BR111 in Patients With Advanced Malignancies

Summary

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.

Timeline

Start

2025-04-24

Primary completion

2027-10-09

Completion

2027-12-31

Drugs

Indications